Directed new share issue in Faron Pharmaceuticals Ltd — EUR 12 million

Carnegie acted as sole bookrunner in Faron Pharmaceuticals’ directed new share issue of 3,692,308 shares at a subscription price of EUR 3.25 per share. Faron Pharmaceuticals is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs caused by dysfunction of our immune system. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology, organ damage and bone marrow regeneration.
January 2023.